Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + R-CP in Relapsed/Refractory Indolent B-Cell Lymphoma and MCL
NCT00295932Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2005
- Primary completion
- Mar 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in B-cell lymphoproliferative disorder, mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
B-cell lymphoproliferative disordermantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00295932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295932.